Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)
Yufei Wang(Fujian Medical University), Wayne A. Marasco(Dana-Farber Cancer Institute), Leo Li‐Ying Chan(Nanjing University of Chinese Medicine), Quan Zhu(Dana-Farber Cancer Institute), Sreekumar Kodangattil(Dana-Farber Cancer Institute), Cecile Razimbaud(Dana-Farber Cancer Institute), Sabina Signoretti(Brigham and Women's Hospital), Catherine J. Wu(Dana-Farber Cancer Institute), Alicia Buck(Unknown), Brandon Piel(Dana-Farber Cancer Institute), Kevin Wei(Brigham and Women's Hospital), Toni K. Choueiri(Harvard University), Miriam Ficial(Barts Health NHS Trust), Rebecca B. Jennings(IHS Markit (United States)), Cloud P. Paweletz(Massachusetts General Hospital), David A. Barbie(Dana-Farber Cancer Institute), Marion Grimaud(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Elena V. Ivanova(Massachusetts General Hospital), Gordon J. Freeman(Dana-Farber Cancer Institute), Matthew Chang(Dana-Farber Cancer Institute), Aedín C. Culhane(Harvard University), Atef Fayed(Georgetown University), Maura Sticco-Ivins(Brigham and Women's Hospital)
Cited by 3
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k